Skip to main content
SpringerLink
Log in

Impact of Hepatitis B Carrier Status on the Outcomes of Surgical Treatment of Colorectal Liver Metastases

  • Original Scientific Report
  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Chronic hepatitis B virus (HBV) infection is associated with a lower incidence of colorectal liver metastases. We explored the impact of HBV carrier status on outcomes of surgical treatment of colorectal liver metastases.

Methods

A retrospective analysis was conducted for consecutive patients undergoing liver resection for colorectal liver metastases from 2000 to 2016. HBV carriers were matched with controls by propensity scoring.

Results

304 patients with known HBV carrier status who underwent resection of colorectal liver metastases were studied. From the 21 (6.9%) hepatitis B carriers, a more prolonged prothrombin time (12.1 vs. 11.3 s, OR 1.42, p = 0.027) was observed, and fewer major resections were performed (19.0 vs. 47.3%, OR 0.262, p = 0.018). After 1:5 propensity score matching, they were compared with 105 controls with similar liver function, tumour status and receiving similar treatments. Patients with chronic hepatitis B enjoyed better median disease-free survival (15.8 vs. 9.20 month, p = 0.032). Overall survivals (50.0 vs. 43.6 month, p = 0.15) were similar. Operating time (227 vs. 240 min, OR 1.00, p = 0.33), blood loss (0.50 vs. 0.37 L, OR 1.15, p = 0.62), hospital stay (6 vs. 6 day, OR 1.02, p = 0.48), operative morbidity (9.5 vs. 16.2%, OR 0.545, p = 0.44) and mortality (0 vs. 1.0%, OR 1.62, p = 0.77) were comparable. The use of antiviral agents did not affect survival of HBV carriers.

Conclusions

Chronic HBV infection confers oncological benefit to surgical treatment of colorectal liver metastases. Given satisfactory liver reserve, HBV carrier status did not affect operative morbidity or mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gomez D, Lobo DN (2011) Malignant liver tumours. Surgery 29:632–639

    Google Scholar 

  2. Geoghegan JG, Scheele J (1999) Treatment of colorectal liver metastases. Br J Surg 86:158–169

    Article  PubMed  CAS  Google Scholar 

  3. Faivre J, Manfredi S, Bouvier AM (2003) Epidemiology of colorectal cancer liver metastases. Bull Acad Natl Med 187:815–822

    PubMed  Google Scholar 

  4. Uetsuji S, Yamamura M, Yamaicchi K et al (1992) Absence of colorectal cancer metastasis to the cirrhotic liver. Am J Surg 164:176–177

    Article  PubMed  CAS  Google Scholar 

  5. Cai B, Liao K, Song XQ et al (2014) Patients with chronically diseased livers have lower incidence of colorectal liver metastases: a meta-analysis. PLoS ONE 9:e108618

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Augustin G, Bruketa T, Korolija D et al (2013) Lower incidence of hepatic metastases of colorectal cancer in patients with chronic liver diseases: meta-analysis. Hepatogastroenterology 60:1164–1168

    PubMed  Google Scholar 

  7. Song E, Chen J, Ou Q et al (2001) Rare occurrence of metastatic colorectal cancers in livers with replicative hepatitis B infection. Am J Surg 181:529–533

    Article  PubMed  CAS  Google Scholar 

  8. Qiu HB, Zhang LY, Zeng ZL et al (2011) HBV infection decreases risk of liver metastasis in patients with colorectal cancer: a cohort study. World J Gastroenterol 17:804–808

    Article  PubMed  PubMed Central  Google Scholar 

  9. Adam R, Lucidi V, Bismuth H (2004) Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am 84:659–671

    Article  PubMed  Google Scholar 

  10. Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1064

    Article  PubMed  PubMed Central  Google Scholar 

  11. Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766

    Article  PubMed  PubMed Central  Google Scholar 

  12. Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sutherland F, Harris JC (2002) Claude Couinaud: a passion for the liver. Arch Surg 137:1305–1310

    PubMed  Google Scholar 

  14. Lisa JR, Solomon C, Gordon EJ (1942) Secondary carcinoma in cirrhosis of the liver. Am J Pathol 18:137–140

    PubMed  PubMed Central  CAS  Google Scholar 

  15. Doherty DG, Norris S, Maridgal-Estebas L et al (1999) The human liver contains multiple populations of NK cells, T cells, and CD3+ CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 163:2314–2321

    PubMed  CAS  Google Scholar 

  16. Okuno K, Hirai N, Lee YS et al (1998) Involvement of liver-associated immunity in hepatic metastasis formation. J Surg Res 75:148–152

    Article  PubMed  CAS  Google Scholar 

  17. Tordjmann T, Soulie A, Guettier C et al (1998) Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. Liver 18:391–397

    Article  PubMed  CAS  Google Scholar 

  18. Song E, Chen J, Ouyan N et al (2001) Kupffer cells of cirrhotic rat livers sensitize colon cancer cells to Fas-mediated apoptosis. Br J Cancer 84:1265–1271

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Seitz G (2008) Warum sind Metastasen in zirrhotischen Lebern so selten? Ultraschall der Medizin 10:123–126

    Article  Google Scholar 

  20. Consolo M, Amoroso A, Spandidos DA et al (2009) Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med 24:143–152

    PubMed  CAS  Google Scholar 

  21. İşlekel H, Oktay G, Terzi C et al (2007) Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct 25:433–441

    Article  PubMed  Google Scholar 

  22. Shalinsky DR, Brekken J, Zou H et al (1999) Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 878:236–270

    Article  PubMed  CAS  Google Scholar 

  23. Abdalla EK, Adam R, Bilchik AJ et al (2006) Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13:1271–1280

    Article  PubMed  Google Scholar 

  24. Fan ST, Lo CM, Poon RT et al (2011) Continuous improvement of survival outcomes of resection of hepatocellular carcinoma. Ann Surg 253:745–758

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong

    Kin Pan Au, Kenneth Siu Ho Chok, Albert Chi Yan Chan, Wing Chiu Dai, Tan To Cheung & Chung Mau Lo

Authors
  1. Kin Pan Au
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth Siu Ho Chok
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Albert Chi Yan Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wing Chiu Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tan To Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chung Mau Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth Siu Ho Chok.

Ethics declarations

Conflicts of interest

The authors declared that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Au, K.P., Chok, K.S.H., Chan, A.C.Y. et al. Impact of Hepatitis B Carrier Status on the Outcomes of Surgical Treatment of Colorectal Liver Metastases. World J Surg 42, 2642–2650 (2018). https://doi.org/10.1007/s00268-018-4483-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-018-4483-3

Search

Navigation